skip navigation links
National Cancer Institute
EVS Logo NCI Term Browser Enterprise Vocabulary Services
Terminologies Value Sets Mappings
Version: 17.12d (Release date: 2017-12-26)
SearchBox Top
SearchBox Bottom
MART-1 Reactive CD8+ T-lymphocytes (Code C111683)

Terms & Properties Synonym Details Relationships Mapping View All  
Terms & Properties

Preferred Name: MART-1 Reactive CD8+ T-lymphocytes

Definition: Human CD8-positive T-lymphocytes that are engineered to recognize melanoma tumor associated antigen MART-1 (Melanoma Antigen Recognized by T cells, also called Melan-A) in a human leukocyte antigen (HLA)-A2-restricted manner, with potential antineoplastic activity. Human peripheral blood lymphocytes (PBLs) are isolated from a melanoma patient, exposed to the MART-1:27-35(27L) peptide and MART-1 specific T-lymphocytes are isolated and expanded. Upon infusion, these lymphocytes recognize and exert a cytotoxic T-cell-mediated immune response against MART-1-expressing melanoma cells. The synthetic MART-1:27-35 HLA-A2-restricted peptide has an amino acid substitution, leucine to alanine at position 27, to increase its immunogenicity.

Display Name: MART-1 Reactive CD8+ T-lymphocytes

Label: MART-1 Reactive CD8+ T-lymphocytes

NCI Thesaurus Code: C111683 (Search for linked caDSR metadata)  (search value sets)

NCI Metathesaurus Link: C3829190  (see NCI Metathesaurus info)

Synonyms & Abbreviations: (see Synonym Details)
MART-1 Reactive CD8+ T-lymphocytes

External Source Codes: 
PDQ Closed Trial Search ID 752696
PDQ Open Trial Search ID 752696 (check for NCI PDQ open clinical trial info)
UMLS CUI C3829190

Other Properties:
     Name Value (qualifiers indented underneath)
code C111683
Contributing_Source CTRP
Semantic_Type Cell
Semantic_Type Pharmacologic Substance

Additional Concept Data: 
Defined Fully by Roles: No  


Mainbox Bottom